---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-051235"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:25:01.223966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma reports record 2023 revenue of $398.2M (+85.9% YoY); non-GAAP EPS $1.96

## Summary
- Q4 2023 total revenue $110.6M (+82% YoY); full-year GAAP net income $71.4M ($0.63 diluted).
- Non-GAAP net income $223.2M ($1.96 diluted) vs. $113.9M ($1.02) in 2022, up 96%.
- FIRDAPSE net revenue $258.4M (+20.8%); FYCOMPA contributed $138.1M since acquisition.
- AGAMREE FDA approval for Duchenne MD; commercial launch on track for Q1 2024.
- FY2024 total revenue guidance $455M-$475M, implying ~14-19% growth vs. 2023.

## SEC filing metadata
- accession: 0001193125-24-051235
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/0001193125-24-051235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/d776053d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-051235
- JSON: https://secwatch.observer/filing/0001193125-24-051235.json
- Plain text: https://secwatch.observer/filing/0001193125-24-051235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.